Immunotherapy Offers Promise for Patients with Recurrent and Metastatic Head and Neck Cancer

Share this content:
At the 2016 ASCO Annual Meeting, presenters discussed the current state and future of immune therapy for patients with head and neck cancer.
At the 2016 ASCO Annual Meeting, presenters discussed the current state and future of immune therapy for patients with head and neck cancer.

Prior to the introduction of immunotherapy, very few options existed for heavily pretreated patients with recurrent and metastatic head and neck squamous cell carcinoma. While several targets for the therapy have been identified, a number of important issues are still being investigated.

In an educational presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, presenters discussed the current state of immunotherapy research and advances in treatment of this patient population. They examined the response dynamics, efficacy, safety, and tolerability of several checkpoint inhibitors, and reviewed several ongoing studies.1

They focused on 2 checkpoint inhibitory mechanisms in particular: the CTLA-4 and PD/PDL1 pathways, which function at initial and later stages of the tumor immune response. A number of clinical trials have investigated the inhibition of these mechanisms both individually and jointly, as well as in combination with other therapies.

“There are a lot of ongoing studies that are looking at a combination of targeted therapy and immune therapy,” said article coauthor Nooshin Hashemi Sadraei, MD, of the University of Cincinnati in Ohio, in an interview with Cancer Therapy Advisor. “We know for a fact that when you add targeted therapy you can have an added or synergistic effect with immune therapy, depending on what setting you're looking at.” 

The article discussed the ongoing search for reliable biomarkers to identify subgroups that will benefit from immunotherapy. Potential candidates include gene expression signatures of the “T-cell inflamed phenotype,” which has been identified as a predictor of clinical benefit from anti-PD1 for patients with head and neck cancer.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters